Results 161 to 170 of about 6,560 (205)

Molnupiravir for COVID-19.

Australian prescriber
openaire   +1 more source

A Nanopore Based Molnupiravir Sensor

ACS Sensors, 2022
Nucleoside analogues are reagents that resemble the structure of natural nucleosides and are widely applied in antiviral and anticancer therapy. Molnupiravir, a recently reported nucleoside analogue drug, has shown its inhibitory effect against SARS-CoV-2.
Wendong Jia, Chengzhen Hu, Yuqin Wang
exaly   +4 more sources

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses [PDF]

Virology, 2021
Endemic seasonal coronaviruses cause morbidity and mortality in a subset of patients, but no specific treatment is available. Molnupiravir is a promising pipeline antiviral drug for treating SARS-CoV-2 infection potentially by targeting RNA-dependent RNA
Kundan Solanki, Zhongren Ma, Maikel P Peppelenbosch   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Molnupiravir for the treatment of COVID-19

Drugs of Today, 2022
Molnupiravir (MK-4482, EIDD-2801) is a promising broad-spectrum experimental antiviral developed by Merck & Co. It is a nucleoside analogue prodrug that undergoes rapid conversion into nucleoside triphosphate (NTP) by intracellular metabolic processes. NTP inhibits viral polymerase by acting as an alternative substrate.
Bela G, Santani, Brian W, LeBlanc, Ritesh P, Thakare   +2 more
openaire   +2 more sources

Molnupiravir is effective in patients with haematological malignancies

International Journal of Cancer, 2023
AbstractPatients with hematologic malignancies are particularly vulnerable to severe infectious complications. SARS‐CoV‐2 infection is associated with a high risk of severe course and death in this patient population. In addition, immune deficits associated with both the blood cancer and the treatment used make vaccination against SARS‐CoV‐2 less ...
Łukasz Bołkun, Bartosz Pula, Agnieszka Kołkowska‐Leśniak, Marta Morawska, Edyta Cichocka, Grzegorz Charlinski, Bartosz Garus, Sebastian Giebel, Jaroslaw Piszcz, Joanna Drozd‐Sokolowska, Jacek Kwiatkowski, Monika Biernat, Iwona Hus, Ewa Lech‐Maranda, Monika Długosz‐Danecka, Krzysztof Giannopoulos, Tomasz Wróbel   +16 more
openaire   +2 more sources

Molnupiravir in COVID-19: A Scoping Review

Current Drug Research Reviews, 2022
Background: COVID-19, first detected in Wuhan, China, has evolved into a lifethreatening pandemic spread across six continents, with the global case count being more than 243 million, and mortality over 4.95 million, along with causing significant morbidity.
Shubham Atal, Shilpa Kaore
openaire   +2 more sources

Molnupiravir

Reactions Weekly, 2023
  +4 more sources

Chemists shorten synthesis of molnupiravir

C&EN Global Enterprise, 2021
Chemists have developed an environmentally friendly route for making the investigational antiviral compound molnupiravir from commodity chemicals in just three steps with 69% overall yield.
openaire   +1 more source